Full Text View
Tabular View
No Study Results Posted
Related Studies
Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid Leukemia
This study has been terminated.
Study NCT00126893   Information provided by Celgene Corporation

First Received on August 3, 2005.   Last Updated on May 14, 2007   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Myeloid Leukemia
Additional conditions recognized in this trial
Leukemia
Leukemia, Myeloid
More general conditions related to this trial
Neoplasms
Neoplasms by Histologic Type
Interventions listed in this trial
CC-401
Sponsors listed in this trial
Celgene Corporation


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services